Want to join the conversation?
$NFX 2Q15 PR: Revenues were $469MM vs. $612MM in 2Q14. Recorded a net loss of $992MM, or $6.09 per diluted share vs. loss of $22MM, or $0.16 per diluted share. The loss was primarily related to a full-cost ceiling test impairment of $1.5Bil ($958MM after-tax, or $5.88 per share).
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)